Abstract
An investigation of the molecular mechanism of the anticancer activity demonstrated by the ruthenium(II)–arene compound [Ru(η6-p-cymene)Cl2(pta)] (pta is 1,3,5-triaza-7-phosphaadamantane), termed “RAPTA-C”, in Ehrlich ascites carcinoma (EAC) bearing mice is described. RAPTA-C exhibits effective cell growth inhibition by triggering G2/M phase arrest and apoptosis in cancer cells. Cell cycle arrest is associated with increased levels of p21 and reduced amounts of cyclin E. RAPTA-C treatment also enhances the levels of p53, and its treatment triggers the mitochondrial apoptotic pathway, as shown by the change in Bax to Bcl-2 ratios, resulting in cytochrome c release and caspase-9 activation. c-Jun NH2-terminal kinase (JNK) is a critical mediator in RAPTA-C-induced cell growth inhibition. Activation of JNK by RAPTA-C increases significantly during apoptosis. Overall, these results suggest a critical role for JNK and p53 in RAPTA-C-induced G2/M arrest and apoptosis of EAC-bearing mice. Consequently, RAPTA-C treatment results in a significant inhibition in the progression of cancer in an animal model, which emulates the human disease, and does so with remarkably low general toxicity; hence, RAPTA-C has potential for clinical application.
Similar content being viewed by others
References
Reedijk J (1987) Pure Appl Chem 59:181–192
Jakupec MA, Galanski M, Arion VB, Hartinger CG, Keppler BK (2008) Dalton Trans 183–194
Wong E, Giandomenico CM (1999) Chem Rev 99:2451–2466
Zanzi I, Srivastava SC, Meinken GE, Robeson W, Mausner LF, Fairchild RG, Margouleff D (1989) Nucl Med Biol 16:397–403
Srivastava SC (1996) Semin Nucl Med 26:119–131
Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JH (2004) Clin Cancer Res 10:3717–3727
Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK (2006) J Inorg Biochem 100:891–904
Hartinger CG, Jakupec MA, Zorbas-Seifried S, Groessl M, Egger A, Berger W, Zorbas H, Dyson PJ, Keppler BK (2008) Chem Biodivers (in press)
Schluga P, Hartinger CG, Egger A, Reisner E, Galanski M, Jakupec MA, Keppler BK (2006) Dalton Trans 1796–1802
Jakupec MA, Reisner E, Eichinger A, Pongratz M, Arion VB, Galanski M, Hartinger CG, Keppler BK (2005) J Med Chem 48:2831–2837
Allardyce CS, Dyson PJ (2001) Platinum Metals Rev 45:62–69
Clarke MJ (2003) Coord Chem Rev 236:209–232
Sulyok M, Hann S, Hartinger CG, Keppler BK, Stingeder G, Koellensperger G (2005) J Anal At Spectrom 20(9):856–863
Timerbaev AR, Hartinger CG, Aleksenko SS, Keppler BK (2006) Chem Rev 106:2224–2248
Aird RE, Cummings J, Ritchie AA, Muir M, Morris RE, Chen H, Sadler PJ, Jodrell DI (2002) Br J Cancer 86:1652–1657
Galeano A, Berger MR, Keppler BK (1992) Arzneimittelforschung 42:821–824
Berger MR, Garzon FT, Keppler BK, Schmähl D (1989) Anticancer Res 9:761–765
Sava G, Bergamo A (2000) Int J Oncol 17:353–365
Seelig MH, Berger MR, Keppler BK (1992) J Cancer Res Clin Oncol 118:195–200
Frasca DR, Gehrig LE, Clarke MJ (2001) J Inorg Biochem 83:139–149
Kratz F, Hartmann M, Keppler B, Messori L (1994) J Biol Chem 269:2581–2588
Pongratz M, Schluga P, Jakupec MA, Arion VB, Hartinger CG, Allmaier G, Keppler BK (2004) J Anal At Spectrom 19:46–51
Polec-Pawlak K, Abramski JK, Semenova O, Hartinger CG, Timerbaev AR, Keppler BK, Jarosz M (2006) Electrophoresis 27:1128–1135
Piccioli F, Sabatini S, Messori L, Orioli P, Hartinger CG, Keppler BK (2004) J Inorg Biochem 98:1135–1142
Kapitza S, Pongratz M, Jakupec MA, Heffeter P, Berger W, Lackinger L, Keppler BK, Marian B (2005) J Cancer Res Clin Oncol 131:101–110
Cauci S, Alessio E, Mestroni G, Quadrifoglio F (1987) Inorg Chim Acta 137:19–24
Kelly JM, Feeney MM, Tossi AB, Lecomte JP, Kirsch-De Mesmaeker A (1990) Anticancer Drug Des 5:69–75
Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G, Geldbach TJ, Sava G, Dyson PJ (2005) J Med Chem 48:4161–4171
Dorcier A, Dyson PJ, Gossens C, Rothlisberger U, Scopelliti R, Tavernelli I (2005) Organometallics 24:2114–2123
Scolaro C, Geldbach TJ, Rochat S, Dorcier A, Gossens A, Bergamo A, Cocchietto M, Tavernelli I, Sava G, Rothlisberger U, Dyson PJ (2006) Organometallics 25:756–765
Ang WH, Daldini E, Scolaro C, Scopelliti R, Juillerat-Jeannerat L, Dyson PJ (2006) Inorg Chem 45:9006–9013
Scolaro C, Chaplin AB, Hartinger CG, Bergamo A, Cocchietto M, Keppler BK, Sava G, Dyson PJ (2007) Dalton Trans 5065–5072
Allardyce CS, Dyson PJ, Ellis DJ, Heath SL (2001) Chem Commun 1396–1397
Reiber M, Reiber MS (2008) Cancer Biol Ther 7 (in press)
Hayward RL, Schornagel QC, Tente R, Macpherson JS, Aird RE, Guichard S, Habtemariam A, Sadler P, Jodrell DI (2005) Cancer Chemother Pharmacol 55:577–583
Gaiddon C, Jeannequin P, Bischoff P, Pfeffer M, Sirlin C, Loeffler JP (2005) J Pharmacol Exp Ther 315:1403–1411
Perrone G, Vincenzi B, Santini D, Verzì A, Tonini G, Vetrani A, Rabitti C (2004) Cancer Lett 208:227–234
Garrido C, Galluzi L, Brunet M, Puig PE, Didelot C, Kroemer G (2006) Cell Death Differ 13:1423–1433
Montaner B, Perez-Tomas R (2002) Ann N Y Acad Sci 973:246–249
Frasca DR, Ciampa D, Emerson J, Umans RS, Clarke MJ (1996) Met Based Drugs 3:197–209
Dyson PJ, Sava G (2006) Dalton Trans 1929–1933
Harris SL, Levine AJ (2005) Oncogene 24:2899–2908
Taylor WR, Stark GR (2001) Oncogene 20:1803–1815
Chen X, Zhang W, Gao YF, Su XQ, Zhai ZH (2002) Cell Res 12:229–233
Jaiswal AS, Bloom LB, Narayan S (2002) Oncogene 21:5912–5922
Coqueret O (2003) Trends Cell Biol 13:65–70
Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massagué J (2001) Nat Cell Biol 3:400–408
Kuo PC, Liu HF, Chao JI (2004) J Biol Chem 279:55875–55885
Choi J, Chiang A, Taulier N, Gros R, Pirani A, Husain M (2006) Circ Res 98:1273–1281
Li Z, Pützer BM (2008) J Cell Mol Med 9999 (in press)
Hengartner MO (2000) Nature 407:770–776
Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN, Ronai Z (1998) Genes Dev 12:2658–2663
Yoshida K, Miki Y (2005) Cell Cycle 4:777–779
Ishikawa Y, Kusaka E, Enokido Y, Ikeuchi T, Hatanaka H (2003) Mol Cell Neurosci 24:451–459
Zu K, Hawthorn L, Ip C (2005) Mol Cancer Ther 4:43–50
Liu J, Lin A (2005) Cell Res 151:36–42
Acknowledgments
The authors are indebted to the Department of Science and Technology, India, and the Indo Swiss Bilateral Research Initiative (EPFL) for funding this research. The support of the the Austrian Science Fund (C.G.H.; Schrödinger Fellowship J2613-N19) and of COST D39 is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chatterjee, S., Kundu, S., Bhattacharyya, A. et al. The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways. J Biol Inorg Chem 13, 1149–1155 (2008). https://doi.org/10.1007/s00775-008-0400-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-008-0400-9